HRTX News and Press, Heron Therapeutics Inc. From 11/13/20

Based on outcome and final minutes of a Type A End- of-Review meeting with FDA in September, Heron Therapeutics (HRTX) has refiled marketing application with the FDA seeking approval for HTX-011 for management of postoperative pain.The submission is classified as a Class 2...

Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain PR Newswire SAN DIEGO, Nov. 13, 2020 SAN DIEGO , Nov. 13, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotec...

Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences PR Newswire SAN DIEGO, Nov. 11, 2020 SAN DIEGO , Nov. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improvin...

Heron Therapeutics (HRTX): Q3 GAAP EPS of -$0.64 misses by $0.01.Revenue of $19.97M (-53.1% Y/Y) beats by $2.79M.Press Release For further details see: Heron Therapeutics EPS misses by $0.01, beats on revenue

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Highlights Recent Corporate Updates PR Newswire SAN DIEGO, Nov. 5, 2020 SAN DIEGO , Nov. 5, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: H...

Our POWR Ratings systems evaluates stocks on a daily basis providing upgraded and downgraded ratings. Here are four recently downgraded stocks that would be best avoided: The Boeing Company (BA), The Dixie Group (DXYN), Heron Therapeutics (HRTX), and Cimarex Energy (XEC). The  POWR ...

As expected, the European Commission approves Heron Therapeutics' ([[HRTX]] +0.9%) Zynrelef (formerly HTX-011), a fixed-dose combination of local anesthetic bupivacaine and nonsteroidal anti-inflammatory med meloxicam, for the treatment of postoperative pain from small-to-medium-sized surgica...

Heron Therapeutics Receives European Commission Authorization for ZYNRELEF™ (HTX-011) for the Treatment of Postoperative Pain PR Newswire SAN DIEGO, Sept. 28, 2020 SAN DIEGO , Sept. 28, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a co...

Heron Therapeutics (NASDAQ: HRTX ) announces  results from EPOCH 2 follow-on study evaluating the efficacy and safety of locally administered HTX-011 300 mg bupivacaine / 9 mg meloxicam into the surgical site in combination with a postoperative non-opioid multimodal analgesia ...

SAN DIEGO , Sept. 16, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced th...